23andMe update: Customers have until July 14 to file data breach claims amid Chapter 11 bankruptcy. Here's how to do it
Some important news for million of 23andMe customers, past and present: the genetic testing company notified customers on Sunday, they now have until July 14 to file potential claims as the company navigates Chapter 11 bankruptcy, according to according to TechCrunch.
The DNA testing firm, which filed for bankruptcy in March, along with 11 of its subsidiaries, must pay customers as part of its bankruptcy restructuring process.
FastCompany has reached out to 23andMe for comment.
23andme, which provided DNA analysis to offer insights into ancestry, health traits, and genetic risks filed for Chapter 11 after it rejected acquisition offers and its market value plummeted in the wake of a massive data breach in 2023.
That breach impacted nearly 7 million users by exposing their names, birth years, relationship labels, percentages of DNA shared with relatives, ancestry reports, and self-reported locations, according to TechCrunch. Multiple class action lawsuits followed, as did mass layoffs, staff in-fighting, while its market value plunged from its 2021 peak at $6 billion.
How can I file a 23andMe claim?
There are three ways 23andme customers can file a claim.
If you were a 23andme customer between May 1 and October 1 2023 can file what is known as a Cyber Security Incident Claim if you were also notified by 23andMe that your personal information was compromised in a data breach that was discovered and disclosed by 23andMe in October 2023.
Alternatively, customers who suffered financial or other damages due to that 2023 breach can submit a claim as part of the bankruptcy case.
Finally, customers who have grievances about the DNA test results or the company's telehealth services, that don't directly pertain to the breach, can submit a claim using the General Bar Date Package.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
States sue 23andMe over genetic data sales
More than two dozen states, along with the District of Columbia, are suing biotechnology company 23andMe over plans to auction off personal genetic information without their customers' knowledge or consent. The lawsuit, which was filed Monday by twenty-seven states in the U.S. Bankruptcy Court in the Eastern District of Missouri, says that the California-based firm, which filed for bankruptcy in March, cannot sell off customers' sensitive data without obtaining consent from each of the individuals. 'New Yorkers and many others around the country trusted 23andMe with their private information and they have a right to know what will be done with their information. My office is joining 27 other attorneys general to protect people's most private information and to make sure 23andMe abides by the law,' New York Attorney General Letitia James (D) said in a news release on Tuesday. The human genetics firm, founded in 2006, filed for Chapter 11 bankruptcy in March in U.S. federal court in Missouri. The company gained popularity for its at-home DNA tests. Customers had to send saliva samples by mail and then they would get genetic reports. 23andMe has collected biological samples and genetic information for more than 15 million consumers. Regeneron Pharmaceuticals, another biotechnology company, said last month that it would purchase for $256 million. When it filed for bankruptcy, 23andMe said the personal information of customers could be accessed, transferred or sold as part of a transaction, but the potential buyers will have to comply with its privacy policies. Regeneron Pharmaceuticals said it would follow the outlined policies and the laws on-hand. Customers can erase their data from the 23andMe site. House lawmakers launched an investigation a month after the biotech company filed for bankruptcy, expressing concerns over the individuals' data and added that some users were unable to delete their information off the website. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
Vermont, New York, New Hampshire sue to stop 23andMe sale
MONTPELIER, Vt. (ABC22/FOX44) – More than two dozen states including Vermont, New York and New Hampshire are suing to block the sale of a once popular genetic testing company. 23andMe is in bankruptcy protection. The company is known for its direct-to-consumer genetic testing services, allowing people to obtain information about their ancestry and potential health conditions. NYS Senate passes Medical Aid in Dying Act Bio-tech company Regeneron Pharmaceuticals requested the court's approval to buy the firm for $256 million, but the states say DNA samples of about 15 million previous customers are too sensitive to allow the transaction without each person giving their informed consent. 'Genetic information is some of the most sensitive information a company can hold about a person,' said Vermont Attorney General Charity Clark. 'It's incredibly personal and forever unchangeable. 'Vermonters' genetic information shouldn't be up for sale without their consent. I am taking action to make sure that Vermonters have the right to decide what happens with their genetic information.' Two found with 'over 100 glassine bags' of fentanyl in Vt. The court has appointed an independent official to examine the proposed sale and its impact on consumer privacy. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
US states sue 23andMe to protect customers' private data
New York and more than two dozen other US states sued 23andMe to challenge the sale of its customers' private information after the genetic testing company filed for bankruptcy in March. Twenty seven states, including Pennsylvania, Michigan and Florida, and the District of Columbia filed the lawsuit on Monday in 23andMe's US bankruptcy proceedings in Missouri, seeking a declaration that it cannot sell customers' genetic data without their consent. California-based 23andMe in a March bankruptcy filing said it was seeking to sell its business at auction after a dip in consumer demand and a data breach in 2023 that exposed genetic and other information of millions of customers. The sale will include more than 15 million DNA profiles that were collected through the company's direct-to-consumer saliva-testing kits. '23andMe cannot auction millions of people's personal genetic information without their consent,' New York Attorney General Letitia James, a Democrat, said in a statement on Tuesday. 'New Yorkers and many others around the country trusted 23andMe with their private information and they have a right to know what will be done with their information.' 23andMe in a statement said the states' arguments were without merit, and that the sale is permitted under 23andMe privacy policies and applicable law. 'Customers will continue to have the same rights and protections in the hands of the winning bidder,' the company said. In a separate filing, Democratic California Attorney General Rob Bonta's office on Monday said the state was objecting to the proposed asset sale because it would violate California's restrictions on the transfer of sensitive genetic material. 23andMe last week told a US bankruptcy judge that it wants to re-open bidding on its assets after receiving a $305 million offer from its co-founder Anne Wojcicki. The company had previously selected a $256 million bid from Regeneron Pharmaceuticals as the lead offer. A representative from Regeneron did not immediately respond to a request for comment.
